As rival Merck monopolizes BCG supply, ImmunityBio taps Serum Institute for new combo's manufacturing

ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, there is an ongoing global shortage of BCG.